Covered recipient · General Payments record
RUCHI PRAVIN KARSALIA
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2022–2024
$503.54
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $387.62 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Biogen, Inc. | $98.89 | 4 |
| Organon LLC | $52.38 | 2 |
| SHIELD THERAPEUTICS INC | $48.42 | 2 |
| Sumitomo Pharma America, Inc. | $47.35 | 2 |
| Agile Therapeutics, Inc. | $47.33 | 2 |
| Daiichi Sankyo Inc. | $27.80 | 1 |
| Evofem Biosciences, Inc. | $23.16 | 1 |
| Astellas Pharma US Inc | $21.94 | 1 |
| PFIZER INC. | $20.35 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics, Inc. | $24.08 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154842949 | CMS |
| Agile Therapeutics, Inc. | $23.25 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154843647 | CMS |
| Astellas Pharma US Inc | $21.94 | 02/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139318806 | CMS |
| Biogen, Inc. | $28.54 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104847832 | CMS |
| Biogen, Inc. | $24.48 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104860394 | CMS |
| Biogen, Inc. | $22.36 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104845492 | CMS |
| Biogen, Inc. | $23.51 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104808973 | CMS |
| Daiichi Sankyo Inc. | $27.80 | 01/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089440627 | CMS |
| Evofem Biosciences, Inc. | $23.16 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091283464 | CMS |
| Organon Llc | $18.45 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136258381 | CMS |
| Organon Llc | $33.93 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136258385 | CMS |
| PFIZER INC. | $20.35 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131627575 | CMS |
| SHIELD THERAPEUTICS INC | $24.75 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150146967 | CMS |
| SHIELD THERAPEUTICS INC | $23.67 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150158577 | CMS |
| Sumitomo Pharma America, Inc. | $25.11 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148872157 | CMS |
| Sumitomo Pharma America, Inc. | $22.24 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148872159 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.